The merger of "sanofi-aventis" as an example for Reasons and Consequences of Mergers and Acquistions in the Pharmaceutical Industry PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The merger of "sanofi-aventis" as an example for Reasons and Consequences of Mergers and Acquistions in the Pharmaceutical Industry PDF full book. Access full book title The merger of "sanofi-aventis" as an example for Reasons and Consequences of Mergers and Acquistions in the Pharmaceutical Industry by Martin Wenderoth. Download full books in PDF and EPUB format.
Author: Martin Wenderoth Publisher: GRIN Verlag ISBN: 3640267036 Category : Business & Economics Languages : en Pages : 19
Book Description
Essay from the year 2008 in the subject Business economics - Offline Marketing and Online Marketing, grade: (4) good, Eötvös Loránd Tudományegytem (International PhD Program), course: Business Economics, language: English, abstract: Within the ongoing globalisation process, many national markets and industrial branches are in different phases of the transition from local to global economic structures (Bryan, L.; Fraser, J.; Oppenheim, J. Rall, W., 2000, pp. 71-95). As a result of this development organisations in the different industries are increasingly concentrating (Brühl, V., 2003, pp. 274-278). Among other industries, also the pharmaceutical industry is highly influenced by the above mentioned trend, reflected by the increasing number of mergers and acquisitions (M&A’s) in the pharmaceutical industry, which is illustrated in the following figure. Figure 1: The present assignment is going to evaluate the reasons and consequences of M&A’s within the pharmaceutical industry by using the sanofi-aventis merger as an example. First of all, the recent history of sanofi-aventis is briefly described. The third part will describe the reasons and consequences of mergers and acquisitions in the pharmaceutical industry by describing the challenges the pharmaceutical branch is confronted with and the respective motives of and results from M&A activities. Finally, the major findings are summarised and conclusions will be derived. 2. History of sanofi-aventis Following the company homepage of sanofi-aventis (20071), the year 1999 has been very im-portant because of two reasons. First of all, Sanofi took over the Synthelabo Holding GmbH and changed its company name to Sanofi-Synthelabo. Furthermore, Hoechst merged with Rhône-Poulenc, a French chemical and pharmaceutical organisation in order to form the new company Aventis, with its legal seat in Strassbourgh (...)
Author: Martin Wenderoth Publisher: GRIN Verlag ISBN: 3640267036 Category : Business & Economics Languages : en Pages : 19
Book Description
Essay from the year 2008 in the subject Business economics - Offline Marketing and Online Marketing, grade: (4) good, Eötvös Loránd Tudományegytem (International PhD Program), course: Business Economics, language: English, abstract: Within the ongoing globalisation process, many national markets and industrial branches are in different phases of the transition from local to global economic structures (Bryan, L.; Fraser, J.; Oppenheim, J. Rall, W., 2000, pp. 71-95). As a result of this development organisations in the different industries are increasingly concentrating (Brühl, V., 2003, pp. 274-278). Among other industries, also the pharmaceutical industry is highly influenced by the above mentioned trend, reflected by the increasing number of mergers and acquisitions (M&A’s) in the pharmaceutical industry, which is illustrated in the following figure. Figure 1: The present assignment is going to evaluate the reasons and consequences of M&A’s within the pharmaceutical industry by using the sanofi-aventis merger as an example. First of all, the recent history of sanofi-aventis is briefly described. The third part will describe the reasons and consequences of mergers and acquisitions in the pharmaceutical industry by describing the challenges the pharmaceutical branch is confronted with and the respective motives of and results from M&A activities. Finally, the major findings are summarised and conclusions will be derived. 2. History of sanofi-aventis Following the company homepage of sanofi-aventis (20071), the year 1999 has been very im-portant because of two reasons. First of all, Sanofi took over the Synthelabo Holding GmbH and changed its company name to Sanofi-Synthelabo. Furthermore, Hoechst merged with Rhône-Poulenc, a French chemical and pharmaceutical organisation in order to form the new company Aventis, with its legal seat in Strassbourgh (...)
Author: Juliane Kuballa Publisher: GRIN Verlag ISBN: 3638592960 Category : Business & Economics Languages : en Pages : 38
Book Description
Seminar paper from the year 2006 in the subject Business economics - Investment and Finance, grade: 80, Northumbria University (Newcastle Northumbria University), language: English, abstract: In the first part, this academic assignment provides general information about motives for international acquisitions. Moreover, it discusses whether foreign exchange markets and stock markets can be said to be efficient. The second part critically analyses the Merger of Sanofi-Synthélabo and Aventis by examining the following aspects: - market position of each company prior to the merger - motives for the proposed merger - attack and defence tactics applied by Sanofi-Synthélabo and Aventis - methods used to finance the merger - share price movements immediately before during and after the proposed take-over (commenting on the benefits to shareholders of each company) - company performance in the period following the take-over (reflecting on the initial take-over motives)
Author: Mennen Publisher: GRIN Verlag ISBN: 3640780582 Category : Business & Economics Languages : en Pages : 65
Book Description
Project Report from the year 2006 in the subject Communications - Public Relations, Advertising, Marketing, Social Media, grade: 65 % - B, University of Sunderland, course: Global Corporate Strategy, language: English, abstract: Mergers and acquisitions are of major importance in the pharmaceutical industry. In order to evaluate the dynamics of this particular industry, this paper critically evaluates the pre- and post- merger situation of GlaxoSmithKline concerning its ready-access to markets, know-how and management capability. Furthermore, strengths and weaknesses and merger's outcomes will be outlined. Critical push and pull factors affecting M&A activity in North America will be analysed, using Pfizer and Pharmacia as an example. In addition, general reasons for M&A failure in the pharmaceutical industry will be illustrated focussing on the M&A activity of GlaxoSmithKline. Finally, using two global pharmaceutical players (GSK and Astrazeneca), the merits and demerits of the McKinsey's five step programme will be discussed.
Author: Dennis Klett Publisher: Grin Publishing ISBN: 9783638717984 Category : Languages : en Pages : 64
Book Description
Bachelor Thesis from the year 2005 in the subject Business economics - Business Management, Corporate Governance, grade: First Class (83%), University of London (School of Management), 52 entries in the bibliography, language: English, abstract: This research paper analyses the strategic and managerial rationale for M&A activity in the pharmaceutical industry in the case of Sanofi-Aventis. The first two sections provide the conceptual and theoretical framework for this research. First, the concepts of M&A and synergy will be defined; then, a selection of the major theories and literature on M&A from the strategic and managerial schools will be introduced and explained. Consequently, according to the deductive logic, the third section will hypothesize the rationale for Sanofi-Synthelabo to acquire Aventis derived from the general theories on M&A. The subsequent sections represent the main part of the research paper, which deals with testing the hypothesis in the case of the Sanofi-Aventis merger. After having stated the hypotheses, the methodology is provided which analyses and justifies the methods used to test the hypotheses. Then, the pharmaceutical industry and its characteristics, as well as both, Sanofi-Synthelabo and Aventis will be briefly analysed. Finally, the hypotheses are tested on their validity through comparison with the key findings of the research, revealing the strategic and managerial rationale for Sanofi-Synthelabo to acquire Aventis.
Author: Mark Thomas Publisher: Taylor & Francis ISBN: 1040008828 Category : Business & Economics Languages : en Pages : 211
Book Description
Covid-19 has brought so much uncertainty, but one certainty is that the vaccine race will generate winners and losers in the pharmaceutical and biotechnology industries. This will have a major impact on merger and acquisition activity. While the plethora of merger and acquisition deals are abundantly reported by the news media, there is a clear lack of in-depth analysis on the multiple rationales and various challenges in the life sciences industry. By offering contributions from a variety of experts in the biotechnology and pharmaceutical industries, as well as experts on mergers and acquisitions, this edited collection will draw upon the knowledge of a variety of different actors within the fields of pharma and biotech. This book offers a timely exploration of the complexities of mergers and acquisitions in the pharmaceutical and biotechnology industries while seeking to bridge the gap between theory and practice. It presents a critical analysis of the rationale for acquisitions and studies the challenges of ensuring a successful deal. In the light of the Covid-19 pandemic, it will also explore the impact this may have on the industry, which may further stimulate merger and acquisition activity. It will be of interest to researchers, academics, policymakers, and students in the fields of strategy, management, governance, and the biotechnology and pharmaceutical industries.
Author: Heiko Schön Publisher: Corporate Finance and Governance ISBN: 9783631663813 Category : Pharmaceutical industry Languages : en Pages : 0
Book Description
This study analyzes 229 M&A and 120 in-licensing deals in the pharmaceutical industry. The author shows from a capital market perspective that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. Significant determinants of success for both strategies are derived.
Author: Jakob Miera Publisher: ISBN: 9783656515432 Category : Languages : en Pages : 96
Book Description
Master's Thesis from the year 2013 in the subject Business economics - Business Management, Corporate Governance, grade: 1,0, language: English, abstract: This thesis deals in general with mergers & acquisitions in the CRO industry, and more specifically with reasons for M&A, success factors during the M&A process, and why M&A can fail in the Contract Research Organization industry. The pharmaceutical industry faces increasing obstacles in respect to the development and introduction of new medications. That has to do with stricter requirements for admission and sharper controls by authorities. Today, the research and development of a new drug can easily consume more than $800 million and lasting between 10 and 15 years. Due to these admission, money and time pressures, pharmaceutical companies are looking for an alternative in the drug development process. A very popular alternative is the outsourcing or in-house working with Contract Research Organizations (CRO). Contract Research Organizations are specialized in coordination and monitoring of drug development activities. Due to their focus they often offer a more sophisticated and faster process. Demographic changes, chronic diseases like cancer and diabetes, and completely new cluster of symptoms demand new therapeutically treatments. The size of the CRO market in 2012 was around $32 billion and had an estimated market growth of around 9 - 12% for 2013. Increased outsourcing and allocation of R&D money towards CRO reflects a driving force for prospective growth. To benefit from the good industry outlooks CROs adjust their service offerings and strengthen their competitive situation. More and more Contract Research Organizations consider mergers & acquisitions as a vital solution to achieve their objectives. Since couple of years we can observe an increased number of deals. Large corporations can close the gaps in the internal service pipeline and smaller firms can use mergers as a financial exit. However, many
Author: Ishrat Rasool Publisher: ISBN: Category : Languages : en Pages : 14
Book Description
Cross-border and domestic merger and acquisitions are considered as fastest means of growth and survival too. This study provides evidence on the value creation by applying inorganic growth strategies based on a sample of Indian pharmaceutical companies. Relying on the key financial ratios, their pre-merger and post-merger financial performances were compared to find whether merger has affected their performance. Based on these multiple financial ratios it has been noted that there was no improvement found in the profitability after merger. The main motives of the mergers and acquisitions like cost reduction, risk spreading etc were compared to the financial results which indicates that the overall motives more or less were achieved by the companies keeping internal factors of acquiring companies constant.
Author: Mohammed Ibrahimi Publisher: John Wiley & Sons ISBN: 1119544289 Category : Mathematics Languages : en Pages : 265
Book Description
This book deals with corporate mergers and acquisitions by analyzing the financial and strategic aspects. It starts with a chronological justification of the evolution of external growth operations and ends with case studies in order to put into practice the theoretical contribution of the previous titles. Through this book, we wish to detail the types of mergers and acquisitions, their modes, their motivations, their consequences and their performances. First of all, we propose a panoply of scientific research, methodological explanations and logical structuring to expose a subject of experience considered for a long time as a phenomenon in finance. Then, through a sample of 90 mergers or acquisitions, we analyze the effects of these transactions on French companies.
Author: Martin Wenderoth
Author: Martin Wenderoth
Author: Juliane Kuballa
Author: Mennen
Author: Dennis Klett
Author: Mark Thomas
Author: Julian Kahl
Author: Heiko Schön
Author: Jakob Miera
Author: Ishrat Rasool
Author: Mohammed Ibrahimi